Oral fexinidazole dosing regimens for the treatment of adults with chronic indeterminate Chagas disease

Photo: DNDi
04/10/2017 - 31/12/2018
Joaquim Gascon
Funded by

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study

The general objective of this clinical trial is to determine the efficacy and safety of alternative dosing regimens of FEXI in reducing and clearing T. cruzi parasitemia in adult individuals with the chronic indeterminate Chagas Disease, in comparison to historical placebo control.

This is  a double-blind, randomized, prospective, comparative, pharmacokineticpharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control. The trial will be conducted in 5 different sites in Spain. The trial will be sufficiently powered to compare the efficacy and safety of each of the dosing regimens of FEXI with historical placebo control. Efficacy and safety will be monitored by an external independent Data Monitoring Committee (DMC) on an ongoing basis. The committee is to include cardiac and liver safety experts, as well as Chagas Disease clinical expertise.

The total duration of patient trial participation will be approximately 14 months.

Our Team


  • Joaquim Gascon
    Joaquim Gascon Research Professor, Director of the Chagas Initiative, head of the Chagas, Parasitic and Imported Diseases programme

ISGlobal team

See More

Other projects

See Past Projects


New Tools for the Diagnosis and Evaluation of Chagas Disease

Control of Leishmaniasis. From bench to bedside and community


Grup de recerca en patología importada i malaties emergents i re-emergents


Antigen-specific immunological biomarkers associated to control of infection by T. cruzi.


Model and Tool for designing strategies to scale up Chagas Disease care


Towards the interruption of transmission of soil-transmitted helminths


New chemotherapy regimens and biomarkers for Chagas Disease


Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.